Dorte Schou Noroxe
Overview
Explore the profile of Dorte Schou Noroxe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fougner V, Urup T, Poulsen H, Grunnet K, Westmose C, Melchior L, et al.
Neurooncol Pract
. 2025 Feb;
12(1):34-44.
PMID: 39917766
Background: In 2016, genomic profiling was implemented for patients with grade 4 primary brain tumors at Rigshospitalet, Denmark. The aim of this study was to discover actionable alterations and to...
2.
Lamoureux A, Fisher M, Lemelle L, Pfaff E, Amir-Yazdani P, Kramm C, et al.
Clin Cancer Res
. 2024 Dec;
31(3):561-572.
PMID: 39625867
Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design:...
3.
Harwood D, Pedersen V, Bager N, Schmidt A, Stannius T, Areskeviciute A, et al.
Nat Commun
. 2024 Sep;
15(1):7857.
PMID: 39251578
Glioblastoma remains one of the deadliest brain malignancies. First-line therapy consists of maximal surgical tumor resection, accompanied by chemotherapy and radiotherapy. Malignant cells escape surgical resection by migrating into the...
4.
Petersen P, Noroxe D
Lancet Haematol
. 2024 Jun;
11(7):e475-e476.
PMID: 38843855
No abstract available.
5.
Noroxe D, Maarup S, Fougner V, Muhic A, Moller S, Urup T, et al.
Neurooncol Adv
. 2023 Dec;
5(1):vdad137.
PMID: 38089638
Background: Glioblastoma is an aggressive brain cancer with no possibility for cure. Treatment and survival have only improved slightly since 2005 when the current regime was implemented. The limited improvements...
6.
Frandsen S, Pedersen A, Gredal O, Moller S, Geissler U, Noroxe D
Int J Circumpolar Health
. 2023 Nov;
82(1):2285077.
PMID: 37992407
Glioblastoma (GBM), WHO grade IV, is the most common primary malignant brain tumour among adults with a devastating overall survival of 14-22 months. Standard treatment of GBM includes maximum safe...
7.
Noroxe D, Flynn A, Yde C, Ostrup O, Nielsen F, Skjoth-Rasmussen J, et al.
Mol Oncol
. 2021 May;
16(1):206-218.
PMID: 34018316
Treatment of glioblastoma (GBM) remains a challenging task, with limited treatment options, none offering a cure. Immune therapy has proven effective across different cancers with remarkable response rates. Tumor mutational...
8.
Noroxe D, Ostrup O, Yde C, Ahlborn L, Nielsen F, Michaelsen S, et al.
Oncotarget
. 2019 Jul;
10(43):4397-4406.
PMID: 31320993
Glioblastoma (GB) is an incurable brain cancer with limited treatment options. The aim was to test the feasibility of using cell-free DNA (cfDNA) to support evaluation of treatment response, pseudo-progression...
9.
Noroxe D, Michaelsen S, Broholm H, Moller S, Poulsen H, Lassen U
Clin Case Rep
. 2019 Mar;
7(2):289-294.
PMID: 30847191
The clinician should always consider extracranial metastases in glioblastoma. Increased risk factors are young age at diagnosis, histology of gliosarcoma, and prior intracranial tumor surgery. Clinical guidelines are needed for...
10.
Fractionated palliative thoracic radiotherapy in non-small cell lung cancer - futile or worth-while?
Stochkel Frank M, Noroxe D, Nygard L, Persson G
BMC Palliat Care
. 2018 Jan;
17(1):15.
PMID: 29304789
Background: Palliative thoracic radiotherapy (PTR) can relieve symptoms originating from intra-thoracic disease. The optimal timing and fractionation of PTR is unknown. Time to effect is 2 months. The primary aim...